Zip-Code Library for Oncology
Various Cancers
Pre-clinicalActive
Key Facts
About Kodikaz Therapeutic Solutions
Kodikaz Therapeutic Solutions is an early-stage biotech (founded 2021) pioneering a proprietary, non-viral targeted delivery platform called Zip-Code™ Technology. The platform is based on the novel discovery of horizontal gene transfer mechanisms in human cells, which Kodikaz engineers into synthetic DNA constructs (TaRGeT Zip-Codes™) that can deliver large payloads like gene editors or cytotoxic agents with high cell specificity. Led by a team with industry and academic expertise, the company is building a library of Zip-Codes for cancer applications, positioning itself to address key limitations of viral gene therapy vectors. It is currently in a pre-clinical, pre-revenue stage.
View full company profileTherapeutic Areas
Other Various Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Oncology/Immuno-oncology Portfolio | MSD | Phase III/Commercial |
| Bevacizumab Biosimilar | Dr. Reddy's Laboratories | Approved |
| LADR Platform | LadRx | Preclinical |
| NK Cell Stimulation (via JadiCell) | Therapeutic Solutions International | Preclinical |
| Proprietary RLT Pipeline | Affibody | Not Specified (Preclinical-Phase 2) |
| Preclinical ASO Portfolio | Isarna Therapeutics | Preclinical |
| SPACE-GM Microenvironment Analysis | Enable Medicine | Research |
| Oncology Program(s) | CIS Pharma | Pre-clinical |
| Max Access Solutions (with The Max Foundation) | Tanner Pharma Group | N/A (Donation/Distribution Program) |
| CPA Platform in Oncology | InnoSIGN | Development |
| Oncology Services | Transcure Bioservices | Preclinical |
| SBX 2021 | Stramsen Biotech | Early-stage Clinical |